MS CONTIN Drug Patent Profile
✉ Email this page to a colleague
When do Ms Contin patents expire, and what generic alternatives are available?
Ms Contin is a drug marketed by Purdue Pharma Lp and is included in one NDA.
The generic ingredient in MS CONTIN is morphine sulfate. There are twenty-three drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ms Contin
A generic version of MS CONTIN was approved as morphine sulfate by HOSPIRA on May 11th, 1988.
Summary for MS CONTIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 24 |
| Clinical Trials: | 7 |
| Patent Applications: | 6,381 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for MS CONTIN |
| What excipients (inactive ingredients) are in MS CONTIN? | MS CONTIN excipients list |
| DailyMed Link: | MS CONTIN at DailyMed |
Recent Clinical Trials for MS CONTIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Medical University Innsbruck | Phase 2 |
| National Institute of Nursing Research (NINR) | Phase 4 |
| Ranbaxy Inc. | Phase 1 |
Pharmacology for MS CONTIN
| Drug Class | Opioid Agonist |
| Mechanism of Action | Full Opioid Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for MS CONTIN
US Patents and Regulatory Information for MS CONTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Purdue Pharma Lp | MS CONTIN | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 019516-003 | Sep 12, 1989 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Purdue Pharma Lp | MS CONTIN | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 019516-004 | Jan 16, 1990 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Purdue Pharma Lp | MS CONTIN | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 019516-001 | May 29, 1987 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Purdue Pharma Lp | MS CONTIN | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 019516-002 | Apr 8, 1988 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Purdue Pharma Lp | MS CONTIN | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 019516-005 | Nov 8, 1993 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MS CONTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Purdue Pharma Lp | MS CONTIN | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 019516-002 | Apr 8, 1988 | ⤷ Try a Trial | ⤷ Try a Trial |
| Purdue Pharma Lp | MS CONTIN | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 019516-004 | Jan 16, 1990 | ⤷ Try a Trial | ⤷ Try a Trial |
| Purdue Pharma Lp | MS CONTIN | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 019516-003 | Sep 12, 1989 | ⤷ Try a Trial | ⤷ Try a Trial |
| Purdue Pharma Lp | MS CONTIN | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 019516-005 | Nov 8, 1993 | ⤷ Try a Trial | ⤷ Try a Trial |
| Purdue Pharma Lp | MS CONTIN | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 019516-001 | May 29, 1987 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MS CONTIN
See the table below for patents covering MS CONTIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | S5698201 | CONTROLLED RELEASE COMPOSITION | ⤷ Try a Trial |
| Ireland | 49324 | CONTROLLED RELEASE COMPOSITIONS | ⤷ Try a Trial |
| Germany | 3048028 | ⤷ Try a Trial | |
| Portugal | 72214 | PROCESS FOR PREPARING CONTROLLED RELEASE COMPOSITIONS | ⤷ Try a Trial |
| Spain | 497906 | ⤷ Try a Trial | |
| United Kingdom | 2067569 | CONTROLLED RELEASE COMPOSITIONS | ⤷ Try a Trial |
| Australia | 541246 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
